Search Within

Subhiksha Nandakumar

  1. "Genitourinary Oncology Service"
Formats
  1. Meeting Abstract (22)
  2. Journal Article (21)
Groups
  1. Department of Medicine (43)
  2. Genitourinary Oncology Service (43)
  3. Solid Tumor Oncology Division (43)
  4. Sloan Kettering Institute Postdocs (36)
  5. GSK Faculty (28)
  6. Human Oncology and Pathogenesis Program (27)

More Groups

People
  1. Philip Kantoff (26)
  2. Nikolaus Schultz (23)
  3. Ying Mazzu (21)
  4. David Solit (20)
  5. Goutam Chakraborty (20)
  6. Michael Berger (16)

More People

Years
  1. 2025 (1)
  2. 2024 (8)
  3. 2023 (2)
  4. 2022 (9)
  5. 2021 (5)
  6. 2020 (8)

More Years

Publications
  1. Cancer Research (10)
  2. Journal of Clinical Oncology (10)
  3. Clinical Cancer Research (8)
  4. Molecular Oncology (4)
  5. Cancer Discovery (2)
  6. European Urology (2)

More Publications

Publishers
  1. American Association for Cancer Research (20)
  2. American Society of Clinical Oncology (10)
  3. FEBS Press (4)
  4. Elsevier Science, Inc. (2)
  5. Nature Publishing Group (2)
  6. Oxford University Press (2)

More Publishers

Results (43)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Bcl-2 inhibitor enhances anti-androgen therapy induced regression of castration sensitive prostate cancer
    Meeting Abstract

    Hirani, R.; Nandakumar, S.; Kalidindi, T.; Fidele, D.; Rajanala, H.; Mazzu, Y.; Yoshikawa, Y.; Jehane, L.; Lee, G. S. M.; de Stanchina, E.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Identification and characterization of the PIK3R1-mutant subtype in PI3K-addicted prostate cancer
    Meeting Abstract

    Chakraborty, G.; Nandakumar, S.; Hirani, R.; Rajanala, S. H.; Nguyen, B.; Ghale, R.; Mazzu, Y. Z.; Jehane, L. E.; Lee, G. S. M.; Mucci, L. A.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Integration of genomic and clinical data from 25,000 patients identifies molecular determinants of metastatic potential and organotropisms
    Meeting Abstract

    Nguyen, B.; Fong, C.; DiNatale, R.; Luthra, A.; Nandakumar, S.; Walch, H.; Chatila, W. K.; Rajanna, A.; Solit, D. B.; Berger, M. F.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Significance of targeting the antiapoptotic pathway in castration-sensitive prostate cancer
    Meeting Abstract

    Chakraborty, G.; Hirani, R.; Nandakumar, S.; Kalidindi, T. M.; Fidele, D.; Rajanala, S. H.; Mazzu, Y. Z.; Yoshikawa, Y.; Jehane, L. E.; Lee, G. S. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality in BRCA2-altered prostate tumors
    Journal Article

    Chakraborty, G.; Khan Patail, N.; Hirani, R.; Nandakumar, S.; Mazzu, Y. Z.; Yoshikawa, Y.; Atiq, M.; Jehane, L. E.; Stopsack, K. H.; Lee, G. S. M.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • CDK12 alterations define a distinct molecular subtype of prostate cancers with unique genomic and clinical characteristics
    Meeting Abstract

    Nguyen, B.; Mota, J. M.; Nandakumar, S.; Stopsack, K. H.; Weg, E.; Rathkopf, D.; Morris, M. J.; Scher, H.; Kantoff, P. W.; Gopalan, A.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Pan-cancer analysis of CDK12 alterations identifies a subset of prostate cancers with distinct genomic and clinical characteristics
    Journal Article

    Nguyen, B.; Mota, J. M.; Nandakumar, S.; Stopsack, K. H.; Weg, E.; Rathkopf, D.; Morris, M. J.; Scher, H. I.; Kantoff, P. W.; Gopalan, A.; more...
    European Urology (2020)

    Fulltext@MSK | Save
  • Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer
    Journal Article

    Mazzu, Y. Z.; Armenia, J.; Nandakumar, S.; Chakraborty, G.; Yoshikawa, Y.; Jehane, L. E.; Lee, G. S. M.; Atiq, M.; Khan, N.; Schultz, N.; more...
    Molecular Oncology (2020)

    Fulltext@MSK | Save
  • Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer
    Journal Article

    Stopsack, K. H.; Nandakumar, S.; Wibmer, A. G.; Haywood, S.; Weg, E. S.; Barnett, E. S.; Kim, C. J.; Carbone, E. A.; Vasselman, S. E.; Nguyen, B.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • The impact of the expression of the transcription factor MYBL2 on outcomes of patients with localized and advanced prostate cancer
    Meeting Abstract

    Yoshikawa, Y.; Wang, X. V.; Chen, Y. H.; Mazzu, Y. Z.; Chakraborty, G.; Jehane, L. E.; Rajanala, S. H.; Hirani, R.; Nandakumar, S.; Stopsack, K. H.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save